

## List of Figures

Figure No.	Figure Captions	Page No.
1.1	Representation of the estimated age-standardized incidence rates of Breast cancer	<b>4</b>
1.2	Geographical distribution of world age-standardised incidence of cervical cancer by country, estimated for 2018	<b>5</b>
1.3	Different application of nanoparticles in cancer research.	<b>6</b>
1.4	Schematic diagram describing the mechanisms implicated in NP-induced ROS production. NPs can be internalized into the cell by (1) endocytosis; (2) formation of the endocytotic vesicles; and (3) release of particle ions from vesicles into the cell.	<b>7</b>
2.1	Depiction of the complex pathway involved in cancer immunotherapy	<b>15</b>
2.2	Folate-mediated delivery of therapeutic agents to folate receptor-positive cancer cells	<b>16</b>
3.1	FT-IR spectra of A) Chemical CuONPs B) CuONPs from <i>A. indica</i>	<b>24</b>
3.2	Hydro dynamic size measurement by DLS A) Chemical Copper oxide nanoparticles B) Copper oxide nano from <i>A. indica</i>	<b>25</b>
3.3	Surface zeta potential of A) Chemically synthesized CuONPs and B) Green synthesized CuONPs from <i>A. indica</i> leaves	<b>25</b>
3.4	X-ray powder diffraction of a) chemical CuONPs b) CuONPs from <i>A. indica</i>	<b>26</b>

3.5	Scanning electron microscopic image A) Chemical CuONPs B) green synthesized CuONPs from <i>A. indica</i>	<b>26</b>
3.6	EDX study a) Chemical CuONPs b) Green CuONPs from <i>A. indica</i>	<b>27</b>
3.7	Transmission electron microscopic image a) Chemical CuONPs b) CuONPs from <i>A. indica</i>	<b>27</b>
3.8	UV-visible spectra of (A) chemically synthesized CuONPs and (B) Green synthesized CuONPs	<b>28</b>
3.9	Ion dissolution study of Chemical CuONPs denoted as U1 and green CuONPs denoted as U2 in a FBS free medium.	<b>29</b>
3.10	Pharmacological activities of chemical and green synthesized CuONPs. (A) DPPH radical scavenging activity (B) IC <sub>50</sub> value of ascorbic acid, chemical and green synthesized CuONPs.	<b>29</b>
3.11	A) H <sub>2</sub> O <sub>2</sub> radical scavenging activity (B) IC <sub>50</sub> value of ascorbic acid, chemical and green synthesized CuONPs.	<b>30</b>
3.12	A) Nitric Oxide radical scavenging activity. (B) IC <sub>50</sub> value of ascorbic acid, chemical and green synthesized CuONPs.	<b>30</b>
3.13	A) Superoxide radical scavenging activity. (B) IC <sub>50</sub> value of ascorbic acid, chemical and green synthesized CuONPs.	<b>31</b>
3.14	GC-MS chromatogram of water extract of leaf of <i>A. indica</i> .	<b>32</b>
4.1	Cell viability assay based on dose and duration dependent percentage of Lymphocytes death by S1NPs, S2NPs and DOX was estimated by MTT assay.	<b>44</b>

4.2	(A) Estimation of Cu ions concentration from S1NPs and S2NPs inside the lymphocytes at different time duration by AAS. (B) Estimation of Cu ions concentration inside the lymphocytes at different time duration by AAS. Here no treatment was done. Only lymphocytes were used to measure Cu ions.	<b>44-45</b>
4.3	Estimation of hemolysis after (A) S1NPs and (B) S2NPs exposure for 24hr.	<b>45</b>
4.4	Estimation of (A) NADPH oxidase level, (B) LDH level from lymphocytes after treatment with S1NPs, S2NPs and DOX for 24hr.	<b>46</b>
4.5	(A) MDA enzymatic level and (B) NO levels from lymphocytes after treatment with S1NPs, S2NPs and DOX for 24hr.	<b>47</b>
4.6	Fluorescence microscopic images of ROS and Apoptotic phenomenon of human lymphocytes. (A,B) Effect of (A) S1NPs and (B) S2NPs on lymphocytes were visualized under fluorescence microscope by DCHF2DA staining with different doses. (C,D) Apoptotic or necrotic event of (C) S1NPs and (D) S2NPs on lymphocytes were visualized under fluorescence microscope by Etbr/AO double staining with different doses with original magnification of 400X. (E) Fluorescence intensity of DCF measured at 485nm excitation and 520nm emission using a fluorescence spectrophotometer. Intensity of control cells was set to 1.00. Data is represented as the fold change of the ROS level in the control group.	<b>48-49</b>
4.7	Cytokines analysis <i>in vitro</i> . Pro and anti-inflammatory response of S1NPs and S2NPs on lymphocytes after 24hr treatment (TNF- $\alpha$ , IL-10).	<b>49</b>

4.8	(A,B) Changes of pro-apoptotic (Caspase-8, Caspase-9, Caspase-3, p38) and anti-apoptotic (pAKT, Bcl2) proteins level after exposure of of S1NPs and S2NPs	<b>50</b>
4.9	Estimation of body weight from animal (A,B) Estimation of body weight of (A) S1NPs and (B) S2NPs treated groups for 15 days.	<b>51</b>
4.10	Estimation of organ weight of Balb/c mice. (A,B) Estimation of organ weight of (A) S1NPs and (B) S2NPs treated groups for 15 days	<b>52</b>
4.11	Estimation of (A,B) SGOT, (C,D) Creatinine from the serum of Balb/c mice after the treatment with S1NPs and S2NPs for 0 days and 15 days.	<b>53</b>
4.12	Estimation of (A,B) LDH levels from the serum of Balb/c mice after the treatment with S1NPs and S2NPs for 0 days and 15 days.	<b>54</b>
4.13	S1NPs or S2NPs levels in animal tissues as indicators of inorganic NPs biodistribution at 1000 µg/mL dose. (A,B) Exhibits the contents of (A) S1NPs or (B) S2NPs in the liver and spleen at both time points. C) Exhibits the contents of S1NPs or S2NPs in the other organs at both time points.	<b>55</b>
4.14	S1NPs or S2NPs levels in blood and feces as indicators of inorganic NPs circulation and elimination at 1000 µg/mL dose. A) Exhibit concentration of S1NPs and S2NPs in blood. B) Concentration of S1 and S2 NPs in feces. Day-0 to day 15 are the time interval during which the NPs were administered	<b>56</b>
4.15	Cytokines analysis <i>in vivo</i> . Analysis of Pro and anti-inflammatory cytokine level of S1NPs and S2NPs treated mice serum after 15 days (TNF- $\alpha$ , IL-10).	<b>57</b>

4.16	Assessment of pro-apoptotic (Caspase-8, Caspase-9, Caspase-3, p38) and anti-apoptotic (pAKT, Bcl2) protein level by ELISA after S1NPs and S2NPs treatment.	57
4.17	Histological images of Liver and Kidney. Histological images of hematoxylin-eosin stained Liver and Kidney of Balb/c mice after treatment with different doses (100-1000µg/mL) of S1NPs and S2NPs after 15 days. The circles in the microscopic image of Liver indicate the areas of leison in liver tissue compared to the control Liver tissue and in case of kidney, the circles indicate histopathological areas of changes due to toxicity compared to the control tissue.	59
5.1	<b>(A)</b> Release of Cu <sup>+2</sup> ions from green synthesized CuONPs at different pH for different time durations. <b>(B)</b> Cu <sup>+2</sup> ions concentration in MCF-7 and HeLa cells after treatment with CuONPs at different time durations, measured by AAS <b>(C)</b> Estimation of free Cu ions in cancer cells measured by AAS without treatment of nanoparticles.	71
5.2	Dose dependent cell death assay of both green synthesized CuONPs and DOX on MCF-7 and HeLa cells.	72
5.3	Cellular redox balance was measured by GSH and GSSG level. <b>(A)</b> Estimation of GSH level from MCF-7 and HeLa cells. <b>(B)</b> Estimation of GSSG level from MCF-7 and HeLa cells.	72
5.4	Estimation of NO release level of green synthesized CuONPs treated MCF-7 and HeLa cells. NO level was expressed as micro mole/mg protein. The levels of NO were expressed as percentage of untreated cells.	73

5.5	(A) Outcome of green synthesized CuONPs on MCF-7 and HeLa cells were visualized under fluorescence microscope by DCHF2DA at a magnification of 40X (B) Control cells intensity was adjusted to 100 unit. Data is represented as fold of change of the ROS level with the control group. Intensity was measured by image J software.	74
5.6	Visualization of nuclear morphology by DAPI staining using fluorescence microscopy at a magnification of 40X were visualized at excitation 330-380 nm and emission 430-460 nm.	75
5.7	Estimation of apoptotic cell population by flow cytometry using Annexin-V/PI staining.	76-77
5.8	ELISA data of Pro (TNF- $\alpha$ ) and anti-inflammatory (IL-10) cytokine level on MCF-7 and HeLa cells after 24 h of treatment of green synthesized CuONPs.	78
5.9	Changes of pro-apoptotic (caspase 8, caspase 3, p38) and anti-apoptotic (pAKT) protein response of green CuONPs on MCF-7 and HeLa cells. (A) Pro and anti-apoptotic protein expression in MCF-7 cells(B) Pro and anti-apoptotic protein expression in HeLa cell.	79
5.10	Changes of pro-apoptotic (caspase 9, cytochrome C and Bax) protein level after treatment with green CuONPs on MCF-7 and HeLa cells. (A) MCF-7 and (B) Pro-apoptotic protein expression in HeLa cells.	80
5.11	Tumor weight of green synthesized CuONPs treated 4T1 infected Balb/c mice. (B) Survival days of green synthesized CuONPs treated 4T1 infected mice.	80

5.12	ELISA data of serum Pro (TNF- $\alpha$ ) and anti-inflammatory (IL-10) cytokine of green synthesized CuONPs on 4T1 cells <i>in vivo</i> model after 24hr treatment.	<b>81</b>
5.13	Changes in the level of of pro-apoptotic (caspase 8, caspase 9, caspase 3, p38, cytochrome C and Bax) and anti-apoptotic (pAKT) proteins after the treatment with green synthesized CuONPs on 4T1 cells. <b>(A)</b> Caspases 3 and 8, p38 and pAKT were estimated from the 4T1 cells of Balb/c mice. <b>(B)</b> Caspase 9, Bax and cytochrome C were estimated from 4T1 cell	<b>82</b>
6.1	FT-IR spectra of I) CuONPs@CS and II) green synthesized CuONPs	<b>91</b>
6.2	XRD pattern of CuONPs@CS	<b>92</b>
6.3	A) Hydrodynamic size measurement of CuONPs@CS by DLS B) Surface zeta potential of CuONPs@CS	<b>92</b>
6.4	SEM image of CuONPs@CS	<b>93</b>
6.5	TGA study of CuONPs@CS	<b>93</b>
6.6	Size measurement by TEM analysis	<b>94</b>
6.7	(A) Dose and duration dependent percentage of lymphocytes death by CuONPs@CS was estimated by MTT assay (B) IC <sub>50</sub> value of CuONPs@CS against lymphocytes.	<b>94</b>
6.8	Estimation of Cu ions concentration from CuONPs@CS inside the lymphocytes by AAS.	<b>95</b>

6.9	(A-G) Effect of CuONPs@CS on lymphocytes were visualized under fluorescence microscope by DCHF2DA staining with different doses. (H) Fluorescence intensity of DCF measured at 485nm excitation and 520nm emission using a spectrofluorometer. Intensity of control cells was set to 1.00. Data is represented as the fold change of the ROS level in the control group	<b>95-96</b>
6.10	Pro and anti-inflammatory level assessment of CuONPs@CS on lymphocytes after 24hr treatment (TNF- $\alpha$ , IL-10). (A) TNF- $\alpha$ (B) IL-12 (C) TGF- $\beta$ and (D) IL-10.	<b>97</b>
6.11	CuONPs@CS on lymphocytes was visualized under fluorescence microscope by Etbr/AO double staining with different doses with original magnification of 400X.	<b>98</b>
6.12	Data of pro-apoptotic (Caspase-8, Caspase-3, p38) and anti-apoptotic (pAKT, Bcl2) protein level after treatment of CuONPs@CS	<b>98</b>
6.13	(A) Assesment of body weight of CuONPs@CS treated groups for 15 days and 30 days. (B) Estimation of organ weight of CuONPs@CS treated groups for 30 days	<b>99</b>
6.14	(A) LDH levels from the serum of Balb/c mice after the treatment with CuONPs@CS for 30 days.(B) Creatinine levels from the serum of Balb/c mice after the treatment with CuONPs@CS for 30 days.(C) SGOT levels from the serum of Balb/c mice after the treatment with CuONPs @CS for 30 days	<b>100</b>
6.15	(A) Pro and anti-inflammatory cytokine changes of CuONPs@CS of mice serum after 30 days (TNF- $\alpha$ , IL-10). (B) Alteration of pro-apoptotic (Caspase-8, Caspase-3, p38) and anti-apoptotic (pAKT, Bcl2) response of CuONPs@CS.	<b>101</b>



7.1	(A) Cell death of MCF-7 and HeLa cells B) IC <sub>50</sub> of MCF-7 C) IC <sub>50</sub> of HeLa cells.	<b>108</b>
7.2	Intracellular uptake of Rh-B tagged CuONPs@CS at a dose of 50µg/ml A) fluorescence image of uptake of CuONPs@CS inside the MCF-7 cells B) Grey scale image of uptake of CuONPs@CS inside MCF-7 cell C) fluorescence image of uptake of CuONPs@CS inside the HeLa cells D) Grey scale image of uptake of CuONPs@CS inside HeLa cells (E) Estimation of Cu ions by AAS inside the cancer cell	<b>109</b>
7.3	Represents the apoptotic phenomenon of cancer cells by Etbr/AO double staining.	<b>110</b>
7.4	Cancer cells were visualized under fluorescence microscope by DCHF2DA staining with different doses at 400 X magnification.	<b>111</b>
7.5	NAC (10mM) pretreatment with cancer cell MCF-7 and HeLa.	<b>112</b>
7.6	(A) Changes of cytokine level in MCF-7 and B) HeLa cells.	<b>112</b>
7.7	Cytotoxicity of CuONPs@CS against the cancer cells pretreated with TNF-α inhibitor Pentoxifyline.	<b>113</b>
7.8	Cancer cells treatment with CuONPs@CS for 24 hr at a dose of 50µg/ml induced apoptosis that was estimated by expression of caspase 8, cleaved caspase 3 and P-p38 proteins by immunofluorescence staining. A) Control MCF-7 B) Treated MCF-7 C) Control HeLa D) Treated HeLa immunofluorescent staining of Caspase 8 E and G are Control MCF-7 and HeLa cells F) & H) are Cleaved caspase 3 expression I) and J) are p-p38 protein expression by immunofluorescence . (M) represents the mean fluorescence intensity of different proteins at a dose of 50 µg/ml of figure 7.8 (A-L) by the help of image J software.	<b>114</b>

7.9	Absorbance value of pro and anti-apoptotic proteins markers. A) Represents the apoptotic proteins expression from MCF-7 cells and B) Represents the apoptotic protein expression from HeLa cells.	<b>115</b>
7.10	Tumor weight of the CuONPs@CS treated group with different doses.	<b>116</b>
7.11	Survival days of Balb/c mice.	<b>117</b>
7.12	Changes of cytokine from Balb/c mice tumor homogenate.	<b>118</b>
7.13	Absorbance of pro-apoptotic (Caspase-8, Caspase-3, p38) and anti-apoptotic (pAKT, Bcl2) markers from tumor homogenate after the treatment of solid tumor bearing mice with CuONPs@CS	<b>119</b>
8.1	(A) Cytotoxicity of CuONPs@CS against Macrophage and lymphocytes at a particular dose of 50µg/ml for 24 hr. (B) Measurement of GSH and (C) GSSG of macrophage and lymphocytes after the application of CuONPs@CS	<b>129</b>
8.2	(A) Fluorescence image of Internalization of Rh-B tagged CuONPs@CS inside the macrophage. B) Grey scale image of Internalization of Rh-B tagged CuONPs@CS inside the macrophage C) Overlay image of Internalization of Rh-B tagged CuONPs@CS inside the macrophage.	<b>130</b>
8.3	A) .Cytotoxicity assay of CuONPs@CS and LPS pulsed macrophage co-culture with MCF-7 cells at a) 5:1 B) 10: 1 and HeLa cells at C) 5:1 and D) 10:1 ratio of macrophage.	<b>131</b>
8.4	Assessment of cytokine released from CuONPs@CS pulsed Macrophage. A) IFN-γ B) IL-10 C) IL-12 and D) TNF-α.	<b>132</b>

8.5	Estimation of viability of cancer cells after co-culture with CuONPs@CS pulsed macrophage with 1:10 ratio in the presence of inhibitor. A) POF B) SAAZ and C) POF and SAAZ together.	<b>133</b>
8.6	CD4+ population was measured by FACS after co-culture with CuONPs@CS pulsed macrophage with 1:10 ratio. A,D,G) Positive Control B,E,H) Negative control C,F,I) CuONPs@CS treated	<b>135</b>
8.7	Cytotoxicity of MCF-7 and HeLa cells after co-culture with cytotoxic T lymphocytes at a 1:10 ratio.	<b>136</b>
8.8	Estimation of LDH from mice serum B) Colorimetric estimation of anti BSA IgG level in serum after second subcutaneous sensitization at an interval of 3 days. C) Estimation of BSA specific IgG1 and D) IgG2 level at day 7.	<b>137</b>
8.9	Spleen cell population by FACS analysis A) Spleen cell of only PBS treated group B) Spleen cell of CuONPs@CS treated group.	<b>138</b>
8.10	Estimation of survivability of Tumor bearing mice after the immunization with different groups for 3 times in a week until day 21.	<b>139</b>
8.11	Reduction in tumor weight after immunization of mice with different groups for 3 times in a week until day 21	<b>140</b>
9.1	FT-IR spectroscopy of (I) Only green synthesized CuONPs (II) CuONPs@CS (III) CuONPs@CS@FA	<b>150</b>
9.2	XRD study of (A) green synthesized CuONPs (B) CuONPs@CS@FA	<b>151</b>
9.3	EDX study of CuONPs@CS@FA	<b>152</b>

9.4	(A) SEM and (B) TEM image of CuONPs@CS@FA	<b>152</b>
9.5	TGA analysis of CuONPs@CS@FA	<b>153</b>
9.6	(A) Estimation of Folic acid binding with CuONPs@CS by spectrophotometrically after different time duration. (B) Intracellular uptake of Cu ions inside MCF-7 & HeLa cell and lymphocytes	<b>154</b>
9.7	(A) Dose and duration dependent percentage of MCF-7 and HeLa cells (B) Lymphocytes death by CuONPs@CS@FA, DOX, CuONPs@CS and only green synthesized CuONPs was estimated by MTT assay	<b>155</b>
9.8	Grey scale, fluorescence and Merged images of Rh-B tagged CuONPs@CS@FA treated MCF-7 cell (A-C) and HeLa cells (D-F) revealed the localization of conjugate NPs.	<b>156</b>
9.9	Visualization of ROS production by DCHF2DA staining inside MCF-7 and HeLa cells via fluorescence microscope after the treatment with CuONPs@CS@FA and DOX. (A) Control MCF-7 and (B) Control HeLa cell (C) treated MCF-7 cells with a dose of 50µg/ml. (D) CuONPs@CS@FA treated HeLa cells with a dose of 50µg/ml. (E) DOX (50µg/ml) treated MCF-7 (F) DOX (50µg/ml) treated HeLa cell (G) DCF fluorescence intensity was expressed in term of ROS production. The data of ROS in control group was set at 100 unit. Treated groups has been presented as a fold change compared to the control group	<b>157</b>
9.10	MMP was determined by measuring Rhodamin-123 fluorescence intensity using fluorescence spectrophotometer.	<b>158</b>

9.11	Displayed membrane integrity and apoptosis by EtBr/AO double staining. (A) Control MCF-7 (B) MCF-7 cells treated with CuONPs@CS@FA (50µg/ml dose). (E) DOX (50µg/ml) treated MCF-7. (C) Control HeLa cells (D) HeLa cells treated with CuONPs@CS@FA (50µg/ml dose). (F) DOX (50µg/ml) treated HeLa cells.	<b>158</b>
9.12	Displayed morphological changes of nuclei by DAPI staining (A) Control MCF-7 (B) MCF-7 treated with CuONPs@CS@FA at a dose of 50µg/ml (C) DOX treated MCF-7 (D) Control HeLa cells (E) HeLa cells treated with CuONPs@CS@FA at a dose of 50µg/ml. (F) DOX treated HeLa cells.	<b>159</b>
9.13	Displayed ultra-structure of MCF-7 and HeLa cells by scanning electron microscopy (A) Control MCF-7 (B) CuONPs@CS@FA treated MCF-7 cells (C) Control HeLa cells (D) CuONPs@CS@FA treated HeLa cells. Arrows in the picture indicate the observed changes.	<b>160</b>
9.14	Estimation of different cell population by flow cytometry using Annexin-V/PI staining.	<b>161</b>
9.15	Determination of cell cycle arrest by flow cytometry (A) untreated MCF-7 cells (B) MCF-7 cells treated with CuONPs@CS@FA (50µg /ml) (C) Untreated HeLa cells (D) HeLa cells treated with CuONPs@CS@FA (50µg /ml).	<b>162</b>
9.16	Cytokines analysis in vitro by ELISA method. Pro and anti-inflammatory (TNF-α, IL-10) response of CuONPs@CS@FA of (A) MCF-7 and (B) HeLa cells.	<b>163</b>

9.17	Caspases activity of MCF-7 and HeLa cells were expressed by immunofluorescent staining process. Here A) Cleaved caspase 3 expression of Control MCF-7 cell B) Cleaved Caspase 3 expression of Treated MCF-7 cells C) Cleaved caspase 3 expression of Control HeLa D) Cleaved Caspase 3 expression of Treated HeLa cells E) ) caspase 8 expression of Control MCF-7 F) ) Caspase 8 expression of Treated MCF-7 cells G) caspase 8 expression of Control HeLa H) Caspase 8 expression of Treated HeLa cells	<b>164</b>
9.18	Western blot analysis of caspase 3 and AKT protein of MCF-7 and HeLa cells.	<b>164</b>
9.19	Dose and duration dependent MTT assay of MCF-7 and HeLa cells after the blocking of Folate receptor of both these cells.	<b>165</b>
9.20	Selection of biologically safe dose in vivo treatment by measurement of body weight of mice for 30 days after the treatment with the CuONPs@CS@FA at an interval of 3 days	<b>165</b>
9.21	(A) Mean weight and (B) images of tumor after the treatment of CuONPs@CS@FA for 30 days at a dose of 1000 µg/Kg body weight. (C) Survival days of Balb/c mice	<b>166</b>
9.22	Pro and anti-inflammatory (TNF- $\alpha$ , IL-10) response of tumor homogenate after the treatment of CuONPs@CS@FA for 30 days at an interval of 3 days.	<b>167</b>